Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3052W HIGH $4.93
Volume
390.76 K
Value Traded
716.73 K
Short % Float
6.14%
Days to Cover
5.5
-14.07%Week
-32.4%1 Month
-16.42%3 Month
+70.32%6 Month
-99.42%5 Year
-99.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
77.23 M
EPS (TTM)
-1.61
P/E Ratio
-
Ent. Value
63.55 M
Total Shares
84.07 M
Float Shares
26.28 M
Insiders
69.87%
Institutions
0.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
QUCY Catalyst Timeline
Dated clinical, regulatory and corporate events for Quantum Cyber N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quantum Cyber N.V.
61Total events
2Upcoming
13Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
TBD
T1Program Discontinuation
Subscribe to view catalyst details
TBD
T2Restructuring Layoffs
Subscribe to view catalyst details
Event history 50
▲Partnership / LicenseCorporate
Exclusive worldwide license to Project LightShift's quantum photonic array technology
▲ATM ProgramCorporate
Termination of at-the-market issuance sales agreement with Maxim Group LLC
●Composition Patent FiledIP / Competition
Provisional patent application filed for Coaxial Dual-Propellant Grain Solid Rocket Motor
▲Equity OfferingCorporate
Warrant holders fully exercise outstanding warrants, resulting in gross proceeds of over $15 million
●Composition Patent FiledIP / Competition
Filed non-provisional utility patent application for EMP-Shielding Composite Filament
▲Patent GrantedIP / Competition
Non-provisional utility patent application filed for EMP-shielding composite filament
▲Partnership / LicenseCorporate
Exclusive IP License Agreement with BP United Inc. for drone technology portfolio
●Composition Patent FiledIP / Competition
Provisional patent application filed for SCOUT-AX6 GUARDIAN quantum-navigated amphibious autonomous ground vehicle
●Management ChangeCorporate
Corporate name change to Quantum Cyber N.V. planned at shareholder meeting
◆Pipeline PrioritizationCorporate
Company to focus on pancreatic cancer detection business in the U.S.
▲Partnership / LicenseCorporate
Discovery and license of a suite of mRNA biomarkers for blood-based pancreatic cancer screening
pancreatic cancersource ↗
▲Partnership / LicenseCorporate
Mainz Biomed enters exclusive licensing agreement with Liquid Biosciences for mRNA biomarkers for pancreatic cancer blood test
pancreatic cancersource ↗
▲Biomarker DataClinical Data
Discovery analysis demonstrates 95% sensitivity and 98% specificity for pancreatic cancer detection using mRNA biomarkers
pancreatic cancersource ↗
▲Quarterly UpdateCorporate
Regained compliance with Nasdaq minimum stockholders' equity requirement
▼Reverse Stock SplitCorporate
Reverse stock split effective and trading begins on split-adjusted basis
▲Partnership / LicenseCorporate
Collaboration agreement with Thermo Fisher Scientific for next-generation CRC screening test
colorectal cancersource ↗
▼Quarterly UpdateCorporate
Nasdaq minimum bid price non-compliance notification and 180-day cure period
▲Oral PresentationColoAlertPresentation
Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO
colorectal cancersource ↗
◆Topline ReadoutColoAlertClinical Data
eAArly DETECT clinical trial results expected in Q4 2023
colorectal cancersource ↗
▲Topline ReadoutColoAlertClinical Data
ColoFuture study topline results: 94% sensitivity, 97% specificity for CRC; 81% sensitivity for advanced adenoma
colorectal cancersource ↗
▲Patent GrantedIP / Competition
Acquired entire IP portfolio for ColoAlert and mRNA biomarkers from Uni Targeting Research and SOCPRA
colorectal cancersource ↗
◆Enrollment CompleteColoFutureTrial
ColoFuture/eAArly DETECT study enrollment completion expected Q1 2023
colorectal cancersource ↗
◆Trial InitiationColoAlertTrial
ReconAAsense study enrollment to start summer 2023
colorectal cancersource ↗
▲Management ChangeCorporate
Nomination of Dr. Heiner Dreismann as Chairman and Gregory Tibbitts to Board of Directors
▼Equity OfferingCorporate
Follow-on public offering of 1,725,000 ordinary shares for gross proceeds of $25,875,000
▼Equity OfferingCorporate
Pricing of follow-on offering of 1,500,000 ordinary shares at $15.00 per share for gross proceeds of $22.5 million
▲Partnership / LicenseCorporate
Mainz Biomed acquires exclusive rights to novel mRNA biomarkers from TTS
colorectal cancersource ↗
◆FDA ApprovalColoAlertFDA Decision
FDA clinical study and submission process intended to be launched in first half of 2022 for U.S. regulatory approval
colorectal cancersource ↗
◆Trial InitiationColoAlertTrial
FDA clinical study and submission process intended to be launched in first half of 2022 for U.S. regulatory approval
colorectal cancersource ↗
◆Timing GuidanceColoAlertPresentation
FDA clinical study and submission process expected to launch in first half of 2022
colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How QUCY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every QUCY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ColoAlert | colorectal cancer | 2023-09-13 | sensitivity colorectal cancer: 94%; specificity colorectal cancer: 97%; sensitivity advanced adenomas: 81%Read More | Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma SensitivitRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| O'Rourke PeterDirector | Grant/Award | 112,859 112,859 held | $0.00 | 07/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QUCY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in QUCY for Q2 2026. | ||||
QUCY Institutional Ownership Trends
QUCY Short Interest
Shares sold short, counted twice a month.
6.14%
Short % of Float
of tradable shares sold short
1.6M
Shares Sold Short
-13.5% vs prior count
5.5 High
Days to Cover
trading days of normal volume to buy every short share back
295.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QUCY ranks across every disease it competes in
Competitive Position is a premium feature
See how QUCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQUCY News
QUCY▼ -9.5%today
Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening
Quantum Cyber N.V. participated in QuantumCT's Phase 3 Pilot Collaboration RFP Convening on October 16, 2026. Presenters Nadab Akhtar and William Skidd discussed the company's antenna technology and its applications in quantum sensing, particularly magnetic navigation. The event fostered collaboration among industry and academic leaders in the quantum innovation ecosystem.
Read more →QUCY▲ +8.7%on this news
Quantum Cyber Appoints Major General (Ret.) Alberto C. Rosende to Board of Directors
Quantum Cyber N.V. appointed Major General (Ret.) Alberto C. Rosende to its Board of Directors. Rosende's extensive military background will aid in completing the Bridgeport, Connecticut manufacturing facility and enhancing the supply chain for autonomous drones. His appointment aligns with the company's strategy to support U.S. defense initiatives.
Read more →QUCYQuantum Cyber Files Audited and Reviewed Financial Statements and Pro Forma Financial Information for Bridgeport Manufacturing Acquisition
Quantum Cyber announced the completion of an independent audit for its recent acquisition of Bridgeport Manufacturing. The audit meets SEC reporting requirements and confirms the transaction's purchase price of $4.18 million, structured as an all-cash deal without goodwill or assumed debt. This acquisition aims to enhance Quantum Cyber's operational capabilities.
Read more →QUCY▼ -10.7%on this news
Quantum Cyber Acquires NVIDIA A100 AI Compute Cluster to Power Its Swarm Operating System
Quantum Cyber N.V. has acquired a Lambda Hyperplane 8-A100 AI compute cluster to enhance its Swarm Operating System, which coordinates drone operations. This move marks a shift to an AI-native defense manufacturer, integrating compute, manufacturing, and command layers. The cluster will enable advanced AI features for autonomous target detection and reduce live test requirements.
Read more →QUCYQuantum Cyber Invites Qualified Foundries, and Prototype-Development Partners to Apply for Its Quantum-Photonic Antenna Manufacturing Program; Responses Due September 18, 2026
Quantum Cyber is inviting qualified partners to apply for its quantum-photonic antenna manufacturing program, aiming to develop a prototype for resilient UAS communications. The deadline for applications is September 18, 2026. This initiative follows the company's licensing agreement with Project LightShift and aligns with U.S. defense priorities, including a substantial budget allocation for drone technology.
Read more →QUCY▲ +8.1%on this newsshared move
Quantum Cyber Appoints Tzvi Lev as Head of Sales, Middle East to Lead GCC Commercial Expansion of Its Autonomous Defense Platform
Quantum Cyber has appointed Tzvi Lev as Head of Sales for the Middle East. Lev, who previously served as Director of Sales and Strategy, will lead the company's expansion in the Gulf Cooperation Council and Israel. His background in defense technology and diplomatic experience positions him to drive commercial engagement in this critical region.
Read more →QUCY▲ +10.6%on this newsshared move
Quantum Cyber Completes Purchase and Installation of 80-Unit 3D Printing Drone Production Farm at Its Bridgeport, Connecticut Manufacturing Facility
Quantum Cyber installed 80 3D printers at its Bridgeport, Connecticut facility. The company completed its first mini-interceptor airframe on July 27, 2026. This move shifts the firm from technology development to domestic defense manufacturing. The production line supports multiple drone product lines using in-house filament.
Read more →QUCYQuantum Cyber Appoints Veteran Distribution Executive Dennis Schnur as Head of U.S. Sales as Company Advances Toward Commercialization of Domestic Drone Production
Quantum Cyber N.V. appointed Dennis Schnur as Head of U.S. Sales to enhance its commercial efforts. This move supports the company's transition to commercializing its domestic drone manufacturing program after acquiring a facility in Bridgeport, Connecticut. The company has already assembled its first mini-interceptor drone at this location.
Read more →QUCYQuantum Cyber Rejects Threat of Future Publications from Short-Seller Adam Gefvert Demanding Withdrawal of $5.69 Million Lawsuit
Quantum Cyber N.V. received a threatening email from short-seller Adam Gefvert, who demanded the withdrawal of a $5.69 million defamation lawsuit in exchange for not publishing further negative reports. The company views this as coercive and plans to continue with the litigation. Quantum Cyber emphasizes the importance of its manufacturing efforts and the broader implications of short-seller activities.
Read more →QUCYQuantum Cyber to Participate in Invitation-Only 1640 Society Hamptons Family Office Wealth Forum 2026
Quantum Cyber N.V. announced its participation in the 1640 Society Hamptons Family Office Wealth Forum 2026. The company will be represented by Peter O’Rourke and Nadab Akhtar on a panel discussing the future of defense technology. Their focus will include autonomous systems and quantum technology's role in defense applications.
Read more →QUCY▲ +8.8%on this newsshared move
Quantum Cyber Unveils the Quantum Photonic Antenna and Publishes Inaugural Technical White Paper Detailing the Quantum Layer of Its Autonomous Defense Platform
Quantum Cyber N.V. has introduced the Quantum Photonic Antenna and published a technical whitepaper detailing its capabilities. This new technology aims to enhance drone warfare and defense applications by capturing a wider range of light. The company also plans to leverage its technology in collaboration with SpaceX, aligning with U.S. defense initiatives.
Read more →QUCYQuantum Cyber Files Lawsuit Against White Diamond Research, Adam Gefvert and Stocktwits, Inc. in New York Supreme Court
Quantum Cyber N.V. has filed a lawsuit against White Diamond Research, Adam Gefvert, and Stocktwits for market manipulation and defamation. The complaint claims that a report published by White Diamond contained false statements and misled investors about the company's financial interests. As a result, Quantum Cyber's stock price dropped significantly, leading to a loss in market capitalization.
Read more →QUCYQuantum Cyber Applauds President Trump's Drone Dominance Program and Supply Chain Framework, Reaffirms Commitment to On-Shore U.S. Manufacturing of Autonomous Systems
Quantum Cyber N.V. praised the Drone Dominance Program Supply Chain Framework, which aims to establish a U.S.-based supply chain for drone production. The company plans to manufacture 100,000 drones annually at its new facility in Bridgeport, Connecticut. Leadership emphasized the importance of domestic manufacturing for national security.
Read more →QUCYQuantum Cyber Completes First Mini-Interceptor Drone at Its Newly U.S. Manufacturing Facility in Bridgeport, Connecticut
Quantum Cyber N.V. completed its first mini-interceptor drone at a new Bridgeport, Connecticut facility. The milestone signals a strategic shift toward domestic manufacturing for counter-UAS applications. The company aims to produce 100,000 drones annually using an in-house 3D printing farm. This aligns with the Department of Defense's $55 billion autonomous warfare budget.
Read more →QUCYQuantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut
Quantum Cyber completed the acquisition of real property in Bridgeport, Connecticut, for $2,300,000. The transaction closed on July 15, 2026, finalizing the real-property component of the Bridgeport deal. This move supports the company's transition to a vertically integrated autonomous defense manufacturer. The facility will serve as the operating foundation for domestic production capabilities.
Read more →QUCYQuantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation
Quantum Cyber N.V. announced approximately $2.09 million in purchase orders through its subsidiary, Quantum Drones Corporation. This development follows the acquisition of a 50,000 square foot manufacturing facility aimed at enhancing U.S.-based production of autonomous defense platforms. The company is led by experienced executives from the U.S. government.
Read more →QUCYQuantum Cyber Files for Drone Launch System Designed to Field Attritable Autonomous Drones at Scale
Quantum Cyber N.V. has filed a provisional patent for a modular drone launch system aimed at deploying autonomous drones efficiently. This system is designed to meet the growing demand for low-cost, scalable drone solutions in defense and border security. The company anticipates significant applications in both military and civilian sectors, aligning with U.S. defense priorities.
Read more →QUCYQuantum Cyber Completes Confidential Submission to U.S. Army Program
Quantum Cyber N.V. has submitted a confidential concept white paper to a U.S. Army program aimed at developing autonomous capabilities for military operations. This submission is part of a competitive process that includes both small and large businesses. The company plans to provide updates on any advancements in the program.
Read more →QUCYQuantum Cyber Targets Annual Production Capacity of 100,000 Drones combining Kamikaze, Interceptor, Surveillance, VTOL and long-range Phantom 950 at Planned Bridgeport, Connecticut Manufacturing Facility
Quantum Cyber N.V. announced plans for a manufacturing facility in Bridgeport, Connecticut, targeting an annual production capacity of 100,000 drones. The facility will support various drone categories, including kamikaze and interceptor systems. The acquisition of the site is part of a strategy to enhance U.S. drone supply chain capabilities amid increasing defense budgets.
Read more →About Quantum Cyber N.V.
HeadquartersROBERT KOCH STRASSE 50, MAINZ
BIOPHARMAWATCH ELITE PLUS
Trade the next QUCY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime